Amylyx Pharmaceuticals In... (AMLX)

NasdaqGS: AMLX · Real-Time Price · USD

37.18

+0.10 (0.27%)

At close: Aug 27, 2026, 8:00 PM

37.30

+0.32%

Pre-market: 5:54 AM

The price, the headline numbers and the latest news, in one place.

0.27% (1D)

No data available

Bid	26.96
Market Cap	4.14B
Revenue (ttm)	n/a
Net Income (ttm)	-152.09M
	-0.20
	-1.41
	n/a
	-32.2
P/B (ttm)	17.31
P/S (ttm)	n/a
Earnings Date	Nov 5, 2026

Ask	47.23
Volume	1,562,823
Avg. Volume (20D)	2,413,858
Open	36.75
Previous Close	37.08
Day's Range	36.53 - 38.23
52-Week Range	9.14 - 41.14
Analyst	n/a
Price Target	n/a
Dividends	n/a
Ex-Dividend Date	n/a

About AMLX

Amylyx Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, engages in the discovery and development of treatment options for neurodegenerative diseases and endocrine conditions in the United States. It provides Avexitide, an investigational, first-in-class glucagon-like peptide-1, or GLP-1 receptor antagonist, which is in phase 3 clinical trial to treat post-bariatric hypoglycemia and congenital hyperinsulinism. The company also devel...

Sector Healthcare

IPO Date Jan 7, 2022

Employees 136

Stock Exchange NasdaqGS

Ticker Symbol AMLX

Website https://amylyx.com

Full Company Profile

Financial Performance

In 2025, Amylyx Pharmaceuticals's revenue was 0, a decrease of -100% compared to the previous year's 87.37M. Earnings were -144.74M, a decrease of -52.03%.

Financial Statements

Earnings Surprise

Amylyx Pharmaceuticals has released their quarterly earnings on Aug 6, 2026:

Revenue of $0 misses estimates by $0, with NaN% YoY growth.
EPS of -0.39 misses estimates by -0.03, with 15.22% YoY growth.

Next Earnings Release

Amylyx Pharmaceuticals Inc. is scheduled to release its earnings on Nov 5, 2026, before market opens.
Analysts project revenue of ... Upgrade

News

2 days ago · Simply Wall St.

Oracle Stock And 2 Growth Picks With Strong Earnings Potential

Germany’s Ifo index has reached a one year high, which hints at a more confident backdrop for companies planning to grow earnings rather than just defend margins. That creates an interesting setting f...

6 days ago · Motley Fool

Why Amylyx Pharmaceuticals Blasted Nearly 79% Higher This Week

The biotech delivered excellent news from the laboratory.

6 days ago · Insider Monkey

Amylyx (AMLX) Faces a Binary Phase 3 Test. Can Avexitide Rebuild the Company?

Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) has released topline results from the Phase 3 LUCIDITY trial of avexitide on August 18, 2026. Shares closed Monday down 0.9% at $21.43, then traded 15.7% hig...